218 related articles for article (PubMed ID: 27655844)
1. The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus.
Durning SP; Preston-Hurlburt P; Clark PR; Xu D; Herold KC;
J Immunol; 2016 Oct; 197(8):3076-3085. PubMed ID: 27655844
[TBL] [Abstract][Full Text] [Related]
2. The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling.
Reed JC; Preston-Hurlburt P; Philbrick W; Betancur G; Korah M; Lucas C; Herold KC
PLoS One; 2020; 15(9):e0236921. PubMed ID: 32986722
[TBL] [Abstract][Full Text] [Related]
3. Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes.
Le Bagge S; Fotheringham AK; Leung SS; Forbes JM
Med Res Rev; 2020 Jul; 40(4):1200-1219. PubMed ID: 32112452
[TBL] [Abstract][Full Text] [Related]
4. Advanced Glycation End Products and Inflammation in Type 1 Diabetes Development.
Du C; Whiddett RO; Buckle I; Chen C; Forbes JM; Fotheringham AK
Cells; 2022 Nov; 11(21):. PubMed ID: 36359899
[TBL] [Abstract][Full Text] [Related]
5. RAGE expression in human T cells: a link between environmental factors and adaptive immune responses.
Akirav EM; Preston-Hurlburt P; Garyu J; Henegariu O; Clynes R; Schmidt AM; Herold KC
PLoS One; 2012; 7(4):e34698. PubMed ID: 22509345
[TBL] [Abstract][Full Text] [Related]
6. All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses.
Oczypok EA; Perkins TN; Oury TD
Paediatr Respir Rev; 2017 Jun; 23():40-49. PubMed ID: 28416135
[TBL] [Abstract][Full Text] [Related]
7. Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.
Leung SS; Forbes JM; Borg DJ
Curr Diab Rep; 2016 Oct; 16(10):100. PubMed ID: 27612847
[TBL] [Abstract][Full Text] [Related]
8. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products.
Chen Y; Yan SS; Colgan J; Zhang HP; Luban J; Schmidt AM; Stern D; Herold KC
J Immunol; 2004 Jul; 173(2):1399-405. PubMed ID: 15240736
[TBL] [Abstract][Full Text] [Related]
9. Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects.
Diggins KE; Serti E; Muir V; Rosasco M; Lu T; Balmas E; Nepom G; Long SA; Linsley PS
JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33351781
[TBL] [Abstract][Full Text] [Related]
10. 22016 ATVB Plenary Lecture: Receptor for Advanced Glycation Endproducts and Implications for the Pathogenesis and Treatment of Cardiometabolic Disorders: Spotlight on the Macrophage.
Schmidt AM
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):613-621. PubMed ID: 28183700
[TBL] [Abstract][Full Text] [Related]
11. Transforming Growth Factor-β1 and Receptor for Advanced Glycation End Products Gene Expression and Protein Levels in Adolescents with Type 1 iabetes Mellitus.
Ninić A; Bojanin D; Sopić M; Mihajlović M; Munjas J; Milenković T; Stefanović A; Vekić J; Spasojević-Kalimanovska V
J Clin Res Pediatr Endocrinol; 2021 Feb; 13(1):61-71. PubMed ID: 32936764
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease.
Reynaert NL; Gopal P; Rutten EPA; Wouters EFM; Schalkwijk CG
Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):403-418. PubMed ID: 27373680
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products as environmental risk factors for the development of type 1 diabetes.
Yap FY; Kantharidis P; Coughlan MT; Slattery R; Forbes JM
Curr Drug Targets; 2012 Apr; 13(4):526-40. PubMed ID: 22250649
[TBL] [Abstract][Full Text] [Related]
14. Alteration of B cell subsets and the receptor for B cell activating factor (BAFF) in paediatric patients with type 1 diabetes.
Parackova Z; Klocperk A; Rataj M; Kayserova J; Zentsova I; Sumnik Z; Kolouskova S; Sklenarova J; Pruhova S; Obermannova B; Petruzelkova L; Lebl J; Kalina T; Sediva A
Immunol Lett; 2017 Sep; 189():94-100. PubMed ID: 28414179
[TBL] [Abstract][Full Text] [Related]
15. AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis.
Nienhuis HL; Westra J; Smit AJ; Limburg PC; Kallenberg CG; Bijl M
Autoimmunity; 2009 May; 42(4):302-4. PubMed ID: 19811283
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on RAGE signaling and its role in cardiovascular disease.
Cohen MM
Am J Med Genet A; 2013 Nov; 161A(11):2750-5. PubMed ID: 24123885
[TBL] [Abstract][Full Text] [Related]
17. Low expression of CD39(+) /CD45RA(+) on regulatory T cells (Treg ) cells in type 1 diabetic children in contrast to high expression of CD101(+) /CD129(+) on Treg cells in children with coeliac disease.
Åkesson K; Tompa A; Rydén A; Faresjö M
Clin Exp Immunol; 2015 Apr; 180(1):70-82. PubMed ID: 25421756
[TBL] [Abstract][Full Text] [Related]
18. The Role of AGE-RAGE Signalling as a Modulator of Gut Permeability in Diabetes.
Snelson M; Lucut E; Coughlan MT
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163688
[TBL] [Abstract][Full Text] [Related]
19. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE.
He CJ; Koschinsky T; Buenting C; Vlassara H
Mol Med; 2001 Mar; 7(3):159-68. PubMed ID: 11471552
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of Tissue Resident Memory CD8 T Cells in Insulitic Lesions in Adult Patients with Recent-Onset Type 1 Diabetes.
Kuric E; Seiron P; Krogvold L; Edwin B; Buanes T; Hanssen KF; Skog O; Dahl-Jørgensen K; Korsgren O
Am J Pathol; 2017 Mar; 187(3):581-588. PubMed ID: 28212742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
